

**Supplementary Table 1.** Characteristics of the patients by enrollment

Characteristic	Enrolled (n=52)	Excluded (n=233)	P value
Age (years)	74.5±12.4	66.8±13.8	<0.001
Sex (male)	21 (40.4)	157 (67.4)	<0.001
Vascular risk factor			
Hypertension	37 (71.1)	148 (63.5)	0.297
Diabetes mellitus	16 (30.8)	76 (32.6)	0.797
Hypercholesterolemia	12 (23.1)	66 (28.3)	0.443
Smoking	9 (17.3)	87 (37.3)	0.006
Atrial fibrillation	18 (34.6)	41 (17.6)	0.006
TOAST stroke classification			0.136
Large artery atherosclerosis	17 (32.7)	85 (37.4)	
Cardiac embolism	8 (15.4)	51 (22.5)	
Small vessel occlusion	18 (34.6)	45 (19.8)	
Undetermined or other determined etiology	9 (17.3)	46 (20.3)	
Initial NIHSS score	12.2 (7-16.5)	5.5 (1-7)	<0.001
Initial NIHSS score, categorical			<0.001
Mild (0-4)	6 (11.5)	142 (60.9)	
Moderate (5-14)	28 (53.8)	67 (28.8)	
Severe (≥15)	18 (34.6)	24 (10.3)	
Treatment			
Intravenous thrombolysis	5 (9.6)	31 (13.3)	0.469
Anti-platelet	37 (71.1)	204 (87.5)	0.003
Aspirin	35 (67.3)	195 (83.7)	0.007
Clopidogrel	21 (40.4)	134 (57.5)	0.025
Anti-coagulation	13 (25.0)	29 (12.4)	0.021
Warfarin	4 (7.7)	15 (6.4)	0.743
NOAC	5 (9.6)	10 (4.3)	0.120
Discharge mRS			<0.001
Favorable (mRS 0-2)	8 (15.4)	161 (69.1)	
Unfavorable (mRS 3-6)	44 (84.6)	72 (30.9)	

TOAST, the trial of ORG 10172 in acute stroke treatment; NIHSS, National Institutes of Health Stroke Scale; NOAC, non-vitamin K antagonist oral anticoagulants; mRS, modified Rankin Scale.

Values are presented as mean±standard deviation, number (%), or median (interquartile range).